Project Grant R33CA302621
Award Date 8/10/26
Completion Date 7/31/29
Dollars Obligated $387K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Cancer Institute awarded The Johns Hopkins University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to engineer messenger RNA–lipid nanoparticle vaccines that direct tissue-specific immune responses to metastatic cancers in vital organs. The research will optimize lipid nanoparticle composition to alter trafficking after intramuscular injection, enabling antigen expression within systemic organs such as the liver and lungs rather than...
- The National Cancer Institute awarded The Johns Hopkins University $149,190 under the Cancer Research Manpower program (CFDA 93.398) on January 22, 2026, for research on CD4+ T cell-activating hydrogels for cancer immunotherapy. The recipient will develop an artificial lymph node (ALN) platform using particulated hyaluronic hydrogel conjugated with signals for optimal T cell activation and expansion. The work encompasses two distinct technologies: MHC II-based ALNs to promote CD4+ cytotoxic T...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute awarded The Johns Hopkins University $644,632 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting gamma-delta T-cell cancers. The award funds research to establish a mechanistic link between genomic alterations in gamma-delta T-cell leukemias and lymphomas and MYC-driven oncogenesis. The recipient will engineer mutations observed in these cancers into normal cells to quantify how genetic...
- The National Cancer Institute awarded The Johns Hopkins University $591,419 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop low molecular weight theranostics targeting cluster of differentiation 38 (CD38) protein for multiple myeloma treatment and detection. The project focuses on two parallel therapeutic tools: an 18F-labeled positron emission tomography imaging agent for improved prognostication of multiple myeloma, and an actinium-225-based targeted...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded The Johns Hopkins University $658,423 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct research on therapeutic targeting of PI3K-gamma-positive tumor-associated macrophages in metastatic castration-resistant prostate cancer with the goal of reducing health disparities. The research addresses the role of tumor-associated macrophages (TAMs) in suppressing immune response...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded The Johns Hopkins University $399,829 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to identify imaging biomarkers using multiplexed digital pathology data to predict clinical outcomes in triple-negative breast cancer. The project applies spatially resolved, high-throughput single-cell computational analysis to characterize tumor microenvironment immune architecture in breast cancer specimens, with the goal of...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...